natgillin/translations-raw huggingface dataset:
Shire will provide an annual update of all published data concerning the efficacy and safety of anagrelide in ET patients as part of the Annual Reassessment.
Shire bo predložil letno posodobitev vseh objavljenih podatkov, ki zadevajo učinkovitost in varnost anagrelida pri bolnikih z ET, v okviru letnega ponovnega poročila o oceni zdravila.
Shivering
drgetanje
Shivering
drgetanje,
Shivering
tresavica
Shivering (chills).
drgetanje (mrzlica)
Shivering may be very commonly observed after vaccination.
Po cepljenju so zelo pogosto opazili tresenje.
Shivering or trembling,
tresenje ali drgetanje,
Shivering or trembling;
tresenje ali drgetanje
Shivering Weakness
mrzlica oslabelost
Shivering/ chills*
Tresenje/ mra-zenje
Shock
šoku;
Shock (including cardiogenic shock)
šok (tudi kardiogeni šok),
Shock (including cardiogenic shock).
šok (vključno s kardiogenim šokom);
Shock due to heart failure
šok zaradi srčnega popuščanja,
Shock including fatal shock
Šok, vključno s šokom s smrtnim izidom
Shock, hypotension, phlebitis.
šok, hipotenzija, flebitis.
Short -acting Opiates
kratkodelujoči opiati
Short acting barbituates, diazepam or paraldehyde may be administered to control seizures.
Za nadzor morebitnih epileptičnih napadov lahko uporabite kratkotrajno delujoče barbiturate, diazepam ali paraldehid.
Short attention span
majhna sposobnost koncentracije
Short bowel syndrome is a condition in which nutrients and fluids are not properly absorbed by the gut, usually following the surgical removal of a large portion of the small intestine.
Sindrom kratkega črevesa je motnja, pri kateri črevo hranilnih snovi in tekočine ne absorbira pravilno, do česar običajno pride po kirurški odstranitvi velikega dela tankega črevesa.
Short duration of therapy (at least 3 months) should be based on transient risk factors (e.g. recent surgery, trauma, immobilisation) and longer durations should be based on permanent risk factors or idiopathic DVT or PE.
Kratkotrajna terapija (vsaj 3 mesece) naj temelji na prehodnih dejavnikih tveganja (n.pr. nedavna operacija, poškodba, imobilizacija), dolgotrajna terapija pa naj temelji na trajnih dejavnikih tveganja ali idiopatski GVT ali PE.
Short duration of therapy (at least 3 months) should be based on transient risk factors (e.g. recent surgery, trauma, immobilisation) and longer durations should be based on permanent risk factors or idiopathic DVT or PE.
Kratkotrajno zdravljenje (najmanj 3 mesece) je indicirano ob prisotnosti prehodnih dejavnikov tveganja (tj. nedavni kirurški poseg, poškodba, imobilizacija), dolgotrajno zdravljenje pa ob prisotnosti trajnih dejavnikov tveganja ali idiopatske GVT ali PE.
Short duration of therapy (at least 3 months) should be based on transient risk factors (e.g. recent surgery, trauma, imobilisation) and longer durations should be based on permanent risk factors or idiopathic DVT or PE.
Kratkotrajno zdravljenje (najmanj 3 mesece) mora temeljiti na prehodnih dejavnikih tveganja (kot so nedavna operacija, poškodba, imobilizacija), dolgotrajnejše pa na trajnih dejavnikih tveganja ali idiopatični GVT ali PE.
Short instructions on how to use Rebif cartridges with each device are given below.
Kratka navodila o uporabi vložkov zdravila Rebif s posamezno napravo so navedena spodaj.
Short-acting antacids should be considered as an alternative to PPIs and administration times of bosutinib and antacids should be separated (i.e. take bosutinib in the morning and antacids in the evening) whenever possible.
Kot o alternativi zaviralcem protonske črpalke bi bilo treba razmisliti o uporabi kratkodelujočih antacidov; če je le mogoče, mora biti čas jemanja bosutiniba in antacidov ločen (npr. bosutinib zjutraj in antacidi zvečer).
Short-term storage
Kratkoročno shranjevanje
Shortage of blood supply, swelling of a vein
laba prekrvavitev, otekanje ven
Shortage of blood supply, swelling of a vein
laba prekrvavitev, otekanje ven,
shortened overall survival and increased deaths attributed to disease progression at 4 months in patients with metastatic breast cancer receiving chemotherapy when administered to target a haemoglobin of 12-14 g/dl (7.5-8.7 mmol/l)
krajšala celotno preživetje in povečala število smrti, ki jih je bilo mogoče pripisati napredovanju bolezni po 4 mesecih, pri bolnicah z metastatskim rakom dojke, zdravljenih s kemoterapijo, če je bila ciljna vrednost hemoglobina od 120 do 140 g/l (od 7,5 do 8,7 mmol/l).
Shortened progression free survival time and increased deaths were observed in the patients receiving Vectibix in combination with bevacizumab and chemotherapy.
Krajši čas preživetja brez napredovanja in več smrti so opazili med bolniki, ki so dobivali zdravilo Vectibix v kombinaciji z bevacizumabom in kemoterapijo.
shortened time to tumour progression in patients with advanced head and neck cancer receiving radiation therapy when administered to target a haemoglobin of greater than
skrajšala čas do napredovanja tumorja pri bolnikih z napredovalim rakom glave in vratu, zdravljenih z obsevanjem, če je bila ciljna vrednost hemoglobina več kot 140 g/l (8,7 mmol/l).
Shortening the treatment duration in patients with genotype 1 and high viral load (HVL) (>800, 000 IU/ml) at baseline who become HCV RNA negative at week 4 and remain HCV RNA negative at week 24 should be considered with even more caution since the limited data available suggest that this may significantly negatively impact the sustained virologic response.
Pri skrajševanju trajanja zdravljenja pri bolnikih z genotipom 1 in visokim virusnim bremenom pred začetkom zdravljenja (> 800.000 i.e./ml), ki postanejo negativni v 4. tednu zdravljenja in so še vedno negativni v 24. tednu zdravljenja, je potrebna še večja pozornost, saj so na voljo le omejeni podatki, ki kažejo, da to lahko signifikantno negativno vpliva na trajen virološki odziv.
Shortness of breath
kratka sapa
Shortness of breath
oteženo dihanje
Shortness of breath
težko dihanje
Shortness of breath
težko dihanje,
Shortness of breath
zadihanost
Shortness of breath
zasoplost,
Shortness of breath
zasoplost;
Shortness of breath
zasoplostjo
Shortness of breath (allergic bronchospasm)
Težko dihanje (alergijski bronhospazem)
Shortness of breath (dyspnoea exertional), upper respiratory infection
težko dihanje (dispneja ob naporu), okužba zgornjih dihal,
Shortness of breath (dyspnoea)
Kratka sapa (dispneja)
Shortness of breath (dyspnoea)
Težko dihanje (dispneja)
Shortness of breath (dyspnoea) in adults
zasoplost (dispneja) pri odraslih
Shortness of breath (dyspnoea).
kratka sapa (dispnea),
Shortness of breath due to muscle cramps of the airways (bronchospasm) occurred in patients with a history of lung problems
Težko dihanje zaradi krča mišic v dihalnih poteh (bronhospazem), ki se pojavlja pri bolnikih, ki so imeli v preteklosti težave s pljuči.
Shortness of breath especially when lying down (which may be a symptoms of heart failure)
zasoplost, zlasti med ležanjem (kar je lahko simptom srčnega popuščanja);
Shortness of breath or any persistent respiratory difficulties.
Kratko sapo ali kakršne koli vztrajne težave z dihanjem.
Shortness of breath with everyday activities or at rest, irregular heartbeat, racing pulse, tiredness, dizziness, and fainting spells, which can be signs of a condition known as pulmonary hypertension
Kratka sapa pri vsakdanjih dejavnostih ali v mirovanju, neredno bitje srca, hitro bitje srca, utrujenost, omotica in napadi omedlevice; to so lahko znaki motnje, imenovane pljučna hipertenzija.
Shortness of breath with exercise
zasoplost pri telesnem naporu
Shortness of breath, cough
kratka sapa, kašelj
Shortness of breath, cough, hoarseness
kratka sapa, kašelj, hripavost
Shortness of breath, cough, which can be due to bronchiectasis (a condition in which the lung airways are abnormally dilated) or pulmonary fibrosis (scarring of the lung).
Kratka sapa, kašelj, ki sta lahko posledici bronhiektazije (stanja, pri katerem so dihalne poti v pljučih nenormalno razširjene) ali pljučne fibroze (brazgotinjenje pljuč).
Shortness of breath, difficult or laboured breathing; cough.
Sopenje, težko ali naporno dihanje, kašelj.
Shortness of breath, sore throat
kratka sapa, vneto žrelo,
Shortness of breath, sore throat or cough
težko dihanje, vnetje žrela ali kašelj
Shortness of breath, sore throat or cough
težko dihanje, vneto žrelo ali kašelj
Shortness of breath, swelling in lung tissue due to infection, inflammation of mouth and tongue.
zasoplost, oteklost pljučnega tkiva zaradi okužbe, vnetje ust in jezika
Shortness of breath, wheezing
zasoplost, sopenje
Shortness of breath.
kratka sapa
Shortness of breath.
zasoplost
Shortness of breath;
kratka sapa
Should a stroke occur or be suspected, DUAVIVE should be discontinued immediately (see section 4.3).
Če se pojavi možganska kap ali sum nanjo, je treba zdravljenje z zdravilom DUAVIVE nemudoma prekiniti (glejte poglavje 4.3).
Should a treated dog mate with a bitch between 6 weeks and 6 months after treatment, appropriate measures should be taken to rule out the risk of pregnancy.
Če se pes, ki je dobil implantat, spari s samico v času od šest tednov do šest mesecev po implantaciji, je treba z ustreznimi ukrepi izključiti tveganje brejosti.
Should a VTE event occur or be suspected, DUAVIVE should be discontinued immediately.
Če se pojavi VTE ali sum na njo, je treba zdravljenje z zdravilom DUAVIVE nemudoma prekiniti.
Should an increase in alanine aminotransferase (ALT) or aspartate aminotransferase (AST) of ≥ 3 X ULN persist, reduction of dose or withdrawal of Pelzont is recommended.
Če zvišanje vrednosti alanin aminotransferaze (ALT) ali aspartat aminotransferaze (AST) na ≥ 3 x ZMN (zgornja meja normalne vrednosti) vztraja, je priporočljivo zmanjšati odmerek zdravila Pelzont ali pa zdravilo Pelzont prenehati uporabljati.
Should an increase in AST or in ALT of 3x ULN or greater persist, withdrawal of Eucreas therapy is recommended.
Če zvišanje AST ali ALT na ali nad 3-kratno zgornjo mejo normalnih vrednosti (ULN - upper limit of normal) vztraja, je priporočena prekinitev zdravljenja z zdravilom Eucreas.
Should any of the conditions appear for the first time during IOA use, the medicinal product should be stopped immediately.
Če se katera od naštetih bolezni ali motenj prvič pojavi prav med jemanjem zdravila IOA, mora ženska nemudoma prenehati z uporabo tega zdravila:
should be 150 mg once daily.
enkrat dnevno.
should be 150 mg once daily.
zdravila Vitekta 150 mg enkrat
should be 150 mg once daily.
zdravila Vitekta 150 mg enkrat dnevno.
should be administered at least
eno uro pred uporabo zdravila
should be administered at least one hour before or two hours after Vitekta (which is administered
Vitekta (ki se daje s hrano) ali dve uri kasneje.
Should be avoided
Se je potrebno izogniti
should be avoided unless the benefit to the patient outweighs the risk.
razen če korist za bolnika pretehta tveganje.
should be considered when used in combination with Nevirapine Teva, particularly for patients in whom reduced susceptibility to lopinavir/ritonavir is suspected.
Pri otrocih je potrebno presoditi o povečanju odmerjanja kombinacije lopinavir/ritonavir do 300/75 mg/m2 2-krat na dan ob jedi, kadar jo uporabljamo v kombinaciji z zdravilom Nevirapin Teva, zlasti pri bolnikih, pri katerih sumimo na zmanjšano občutljivost za kombinacijo lopinavirja in ritonavirja.
should be considered.
Bolnike je treba natančno nadzorovati glede pojava
should be considered.
zoldipem
should be discontinued during treatment with posaconazole as increased levels have been associated with rhabdomyolysis (see section 4.3).
Pri sočasni uporabi posakonazola z zaviralci HMG-CoA reduktaze je potrebno zdravljenje prekiniti, ker so bile zvišane koncentracije povezane z rabdomiolizo (glejte poglavje 4.3).
should be done, see section
glejte poglavje
should be guided by clinical
povečati glede na klinični odziv,
should be increased by 50%
je treba dnevni odmerek rifabutina
Should be swallowed whole, do not chew or break the capsule.
Kapsule pogoltnite cele, ne žvečite in ne lomite.
Should be used within 6 hours after first broaching of the vial
Uporabiti morate v 6 urah po prvem vbodu v vialo.
Should diarrhoea occur during treatment with oral topotecan, physicians are advised to aggressively manage diarrhoea.
Če se driska pojavi med zdravljenjem s peroralnim topotekanom, mora zdravnik odločno ukrepati, da bi jo obvladal.
Should diarrhoea occur during treatment with oral topotecan, physicians are advised to aggressively manage diarrhoea.
Če se pojavi med zdravljenjem s peroralnim topotekanom, mora zdravnik odločno ukrepati, da bi jo obvladal.
Should extravasation occur, flushing the site with sodium chloride 9 mg/ml (0.9%) solution for injection and/or sterile water and applications of ice are recommended.
Če pride do ekstravazacije, se priporoča izpiranje mesta z 9 mg/ml (0,9 %) raztopino natrijevega klorida za injiciranje in/ali sterilno vodo ter ledeni obkladki.
Should extravasation occur, flushing the site with sodium chloride 9 mg/ml (0.9%) solution for injection and/or sterile water and applications of ice are recommended.
Če pride do ekstravazacije, se priporoča izpiranje mesta z natrijevim kloridom 9 mg/ml (0,9 %) raztopino za injiciranje in/ali sterilno vodo ter ledeni obkladki.
Should I expect side effects for my dog during Masivet therapy?
Ali naj pri svojem psu med zdravljenjem z zdravilom Masivet pričakujem stranske učinke?
Should not be performed
ga ne določamo
Should not be used in animals suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders.
Ne uporabite pri mačkah z obolenji prebavil, kot so zdraženost prebavil in krvavitve, oslabljeno delovanje jeter, srca ali ledvic ter hemoragične motnje.
Should not be used in case of hypersensitivity to the active substance or to any of the excipients.
Ne uporabite v primeru preobčutljivosti na zdravilno učinkovino ali na katero koli pomožno snov.
Should not be used in cats less than 6 weeks old.
Ne uporabite pri mačkah, mlajših od 6 tednov.
Should not be used in pregnant or lactating animals.
Ne uporabite pri brejih mačkah in mačkah v obdobju laktacije.
Should seizures not be adequately controlled, further diagnostic measures and other antiepileptic treatment should be considered.
Če epileptičnih napadi niso ustrezno obvladani, je treba razmisliti o dodatnih diagnostičnih ukrepih in drugemu zdravljenju proti epilepsiji.
Should subsequent surgery be intended in a dog previously treated with Recuvyra, a minimum of a 7 day dosing interval must be observed before administering another dose.
Če je treba pri psu, ki mu je že bilo dano to zdravilo, izvesti naslednjo kirurško operacijo, morate pred dajanjem naslednjega odmerka narediti najmanj 7-dnevni presledek.
Should subsequent surgery be intended in a dog previously treated with the veterinary medicinal product, a minimum of a 7 day dosing interval must be observed before administering another dose
Če je treba pri psu, ki mu je bilo že dano zdravilo, izvesti naslednjo kirurško operacijo, morate pred dajanjem naslednjega odmerka narediti najmanj 7-dnevni presledek.
Should subsequent surgery be intended in a dog previously treated with the veterinary medicinal product, a minimum of a 7 day dosing interval must be observed before administering another dose.
Če je treba pri psu, ki mu je bilo že dano to zdravilo, izvesti naslednjo kirurško operacijo, morate pred dajanjem naslednjega odmerka narediti najmanj 7-dnevni presledek.
Should the physician decide to administer anticoagulation in the context of epidural/spinal anaesthesia or lumbar puncture, it is necessary to exercise caution and regular monitoring of the patient to detect possible signs and symptoms of neurological impairment such as midline back pain, sensory and motor deficits (numbness or weakness in the lower limbs), bowel and/or urinary bladder dysfunction.
Če se zdravnik odloči, da bo v okviru epiduralne/spinalne anestezije ali lumbalne punkcije uporabil antikoagulacijsko zdravljenje, sta potrebna previdnost in redni nadzor bolnika, da bi pri njem odkrili morebitne znake in simptome nevrološke okvare, npr. bolečino v srednji črti hrbtenice, senzorične in motorične izpade (omrtvelost ali šibkost spodnjih udov) ter moteno delovanje črevesa in/ali sečnega mehurja.
Should these symptoms occur, adequate action should be taken to correct the low blood glucose (oral carbohydrates).
Če se ti simptomi pojavijo, je treba ustrezno ukrepati, da bi odpravili nizko glukozo v krvi (zaužitje ogljikovih hidratov).
Should this occur, re-application is not necessary; however, contact with treated areas (application sites) should be avoided until dry.
Če bi se to zgodilo, ponovno nanašanje ni potrebno, vendar se ne dotikajte zdravljenih mest, dokler niso suha.
Should this occur, re-application is not necessary; however, contact with treated areas (application sites) should be avoided until dry.
Če bi se to zgodilo, ponovno nanašanje ni potrebno; vendar se ne dotikajte zdravljenih mest, dokler niso suha.
Should treatment be interrupted, Humira 40 mg every week may be re-introduced (see section 5.1).
Če je potrebno z zdravljenjem prekiniti, lahko ponovno uvedete zdravljenje z zdravilom Humira odmerkom 40 mg vsak teden (glejte poglavje 5.1).
Should treatment be interrupted, Humira 40 mg every week may be re-introduced (see section 5.1).
Če je potrebno z zdravljenjem prekiniti, lahko ponovno uvedete zdravljenje z zdravilom Humira z odmerkom 40 mg vsak teden (glejte poglavje 5.1).
Should treatment with any of these agents be required, it is recommended that therapy with Tasigna be interrupted if possible (see section 4.5).
Če je potrebno zdravljenje s katerim od teh sredstev, je priporočljivo, če je le mogoče, prekiniti zdravljenje z zdravilom Tasigna (glejte poglavje 4.5).
Should vaccination with live vaccines be indicated after initiation of Ilaris treatment, the recommendation is to wait for at least 3 months after the last Ilaris injection and before the next one (see section 4.4).
Če je cepljenje z živim cepivom indicirano po začetku zdravljenja z zdravilom Ilaris, je priporočeno s cepljenjem počakati vsaj 3 mesece po zadnji injekciji zdravila Ilaris in zdravljenje z zdravilom Ilaris nadaljevati šele 3 mesece po cepljenju (glejte poglavje 4.4).
Should you experience any reaction like this, please tell your doctor immediately.
Če pride do take reakcije, morate nemudoma obvestiti zdravnika.
Should you have any further question on the use of Cuprymina, please ask the nuclear medicine doctor who supervises the procedure.
V primeru dodatnih vprašanj o uporabi radiofarmacevtskega predhodnika Cuprymina se posvetujte z zdravnikom nuklearne medicine, ki nadzoruje postopek.
Should you have any questions, ask your pharmacist.
Če imate o tem kakršnokoli vprašanje, se posvetujte s farmacevtom.
Should your doctor decide to stop your Levetiracetam Actavis treatment, he/she will instruct you about the gradual withdrawal of Levetiracetam Actavis.
Če se bo vaš zdravnik odločil za prekinitev zdravljenja z zdravilom Levetiracetam Actavis, vam bo dal napotke o postopni ukinitvi zdravila Levetiracetam Actavis.
Should your doctor decide to stop your Levetiracetam Teva treatment, he/she will instruct you about the gradual withdrawal of Levetiracetam Teva.
Če se bo vaš zdravnik odločil za prekinitev zdravljenja z zdravilom Levetiracetam Teva, vam bo dal napotke o postopni ukinitvi zdravila Levetiracetam Teva.
Show the Patient Alert Card and this package leaflet to any doctor involved with your treatment, not only to your neurologist.
Opozorilno kartico bolnika in to navodilo za uporabo pokažite vsem zdravnikom, ki vas zdravijo, ne le svojemu nevrologu.
Show them the pack of tablets.
Pokažite jim škatlo zdravila.
Show this card to any doctor involved in your treatment.
Opozorilno kartico za bolnika pokažite vsakemu zdravniku, ki sodeluje pri vašem zdravljenju.
Show this card to any doctor involved in your treatment.
To kartico pokažite vsem zdravnikom, ki sodelujejo pri vašem zdravljenju.
Show this card to any doctor, nurse or dentist you see - not just the specialist who prescribes your MabThera.
Pokažite jo vsem zdravnikom, medicinskim sestram in zobozdravnikom, ki jih obiščete – ne samo specialistu, ki vam predpiše zdravilo MabThera.
Shown on the oral dispenser are marks for 30 mg, 45 mg and 60 mg of the medicine (see figures in Instructions for the user).
Na peroralnem odmerniku so oznake za odmerjanje 30 mg, 45 mg in 60 mg zdravila (glejte slike v Navodilih za uporabnika).
shown reproductive toxicity (see section 5.3).
Študije na živalih so pokazale vpliv na sposobnost razmnoževanja (glejte poglavje 5.3).
Shunt thromboses may occur, especially in patients who have a tendency to hypotension or whose arteriovenous fistulae exhibit complications (e.g. stenoses, aneurisms), see section 4.4. In most cases, a fall in serum ferritin values simultaneous with a rise in packed cell volume is observed (see section 4.4).
Mogoče so obvodne tromboze, posebno pri bolnikih, nagnjenih k nizkemu krvnemu tlaku ali s spremembami na arteriovenskih fistulah (npr. stenoze, anevrizme), glejte poglavje 4.4. Pri večini bolnikov spremlja povečanje hematokrita padec feritina v serumu (glejte poglavje 4.4).
Shunt thrombosis Thrombocytosis
obvodna tromboza trombocitoza
Shunt thrombosis*
tromboza spoja
SI
HR
SI PhA FarMed d.o.o., Slovenija, Tel: +386 40 873319, pha.farmed@siol.com
SI PHA FARMED d.o.o., Slovenija, Tel: +386 40 873319, phafarmed@phafarmed.com
SI unit = mol/l)
SI-enote (mol/l)
SI-1526 Ljubljana Slovenia
1526 Ljubljana Slovenija
SIA AstraZeneca Latvija Tel: +371 67377100
SIA AstraZeneca Latvija Tel: + 371 67377 100
SIA AstraZeneca Latvija Tel: +371 67377100
Αλέκτωρ Φαρµακευτική Λτδ Τηλ: +357 22490305
sia,
o),
Sialanar 320 micrograms /ml oral solution
Sialanar 320 mikrogramov/ml peroralna raztopina
Sialanar is not recommended in children aged <3 years in the symptomatic treatment of sialorrhoea (chronic pathological drooling) (see section 4.4).
Uporaba zdravila Sialanar se odsvetuje pri simptomatskem zdravljenju sialoreje (kroničnega patološkega slinjenja) pri otrocih, mlajših od 3 let (glejte poglavje 4.4).
Sialanar must not be given if the patient is pregnant (or could be pregnant), or is breast-feeding (see section 2 ‘Do not give’).
Zdravilo Sialanar se ne sme uporabljati pri nosečnicah (ali potencialnih nosečnicah) ali ob dojenju (glejte poglavje 2 Otrok ali mladostnik ne sme uporabljati zdravila Sialanar:).
Sialanar should be taken by mouth.
Zdravilo Sialanar je namenjeno peroralni uporabi.
sicca syndrome
Sjögrenov sindrom
Sick and debilitated dogs and cats should only be premedicated with dexmedetomidine before induction and maintenance of general anaesthesia based on a risk-benefit assessment.
Pri bolnih ali oslabljenih psih in mačkah se lahko uporabi deksmedetomidin za premedikacijo pred uvajanjem in vzdrževanjem splošne anestezije šele po oceni koristi in tveganja postopka.
Sick sinus syndrome
bolezen sinusnega vozla
Sick sinus syndrome
Bruhanje Driska
Sick sinus syndrome
indrom bolnega sinusnega vozla
Sick sinus syndrome
sindrom bolnega sinusnega vozla
Sick-sinus syndrome
Bolezen sinusnega vozla
SICKLE CELL ANAEMIA
ANEMIJA SRPASTIH CELIC
Sickle cell crisis has been associated with the use of G-CSF or derivatives in patients with sickle cell anaemia (see section 4.8).
Srpastocelična kriza je povezana z uporabo G-CSF ali derivatov pri bolnikih s srpastocelično anemijo (glejte poglavje 4.8).
Sickle cell crisis has happened in some patients with Sickle Cell Disease who have been given filgrastim.
Pri nekaterih bolnikih s srpasto anemijo, ki so prejemali filgrastim, je prišlo do srpastocelične krize.
Sickle cell crisis2; Splenomegaly2; Splenic rupture2
rpastocelična kriza2, splenomegalija2, ruptura vranice2
Sickle cell crisisa
srpastoceličn a krizaa
Sickle cell crisisa
srpastocelična krizaa
Sickle cell disease
Srpastocelična anemija
Sickle Cell disease is an inherited blood disorder that affects the disc shaped red cells of the blood.
Srpasto celični sindrom je dedna bolezen, ki vpliva na rdeče krvne celice v obliki ploščice.
Sickle cell trait and sickle cell disease
Prenašalci srpastocelične anemije in bolniki s srpastocelično anemijo